title: Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), ketanserin, and (R)-(+)-{alpha}-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol (MDL100907) in rats.
abstract: Very little is known about constitutive activity in vivo. This study examined whether constitutive activity and inverse agonism contribute to discriminative stimulus effects of drugs acting at serotonin (5-HT)(2A) receptors. Rats were trained to discriminate between saline and either 0.56 mg/kg 5-HT(2) receptor agonist 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), 1.0 mg/kg 5-HT(2A) receptor antagonist ketanserin, or 0.1 mg/kg purported 5-HT(2A) receptor inverse agonist (R)-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol (MDL100907). Discriminative control was established with each drug after 33 to 35 sessions. MDL100907 and ketanserin did not occasion DOM lever responding but attenuated the discriminative stimulus effects of DOM. DOM did not occasion responding on the drug-associated lever in rats discriminating MDL100907 or ketanserin, but attenuated the discriminative stimulus effects of both drugs. Ketanserin and ritanserin occasioned MDL100907-lever responding, whereas rats discriminating ketanserin responded only partially on the drug-associated lever after receiving MDL100907, ritanserin, or the alpha(1)-adrenergic antagonist prazosin. Combining prazosin with MDL100907 or ritanserin resulted in near-complete ketanserin-lever responding, indicating that the ketanserin stimulus involves both 5-HT(2A) and alpha(1)-adrenergic receptors. Administration of p-chlorophenylalanine methyl ester, then fenfluramine, significantly decreased cortical 5-HT, enhanced sensitivity to the discriminative stimulus effects of DOM, and occasioned partial MDL100907-lever responding. Collectively, these results show that DOM and MDL100907 discriminative stimulus effects are mediated by 5-HT(2A) receptors and that ketanserin discriminative stimulus effects involve both 5-HT(2A) and alpha(1)-adrenergic receptors. Results in 5-HT-depleted rats further suggest that the discriminative stimulus effects of MDL100907 might involve antagonism of endogenous 5-HT and/or inverse agonism at 5-HT(2A) receptors.
authors.affiliation: Department of Pharmacology, University of Texas Health Science Center at San Antonio, TX 78229, USA.
authors.forename: Jun-Xu
authors.initials: JX
authors.lastname: Li
authors.forename: Alison
authors.initials: A
authors.lastname: Unzeitig
authors.forename: Martin A
authors.initials: MA
authors.lastname: Javors
authors.forename: Kenner C
authors.initials: KC
authors.lastname: Rice
authors.forename: Wouter
authors.initials: W
authors.lastname: Koek
authors.forename: Charles P
authors.initials: CP
authors.lastname: France
mesh_terms: D004290:DOM 2,5-Dimethoxy-4-Methylamphetamine / Q000494:pharmacology*; D000701:Analgesics, Opioid / Q000494:pharmacology; D000778:Anesthetics, Dissociative / Q000494:pharmacology; D000818:Animals; D003216:Conditioning, Operant / Q000187:drug effects; D004192:Discrimination, Psychological / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005464:Fluorobenzenes / Q000494:pharmacology*; D007649:Ketamine / Q000494:pharmacology; D007650:Ketanserin / Q000494:pharmacology*; D008297:Male; D009020:Morphine / Q000494:pharmacology; D010622:Phencyclidine / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044402:Receptor, Serotonin, 5-HT2A / Q000187:drug effects; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects; D016713:Ritanserin / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*
chemical_list: D000701:Analgesics, Opioid; D000778:Anesthetics, Dissociative; D018691:Excitatory Amino Acid Antagonists; D005464:Fluorobenzenes; D010880:Piperidines; D044402:Receptor, Serotonin, 5-HT2A; D018340:Receptors, Adrenergic, alpha-1; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D016713:Ritanserin; D004290:DOM 2,5-Dimethoxy-4-Methylamphetamine; D007649:Ketamine; D009020:Morphine; D007650:Ketanserin; C079049:volinanserin; D010622:Phencyclidine
references.citation: Gen Pharmacol. 2000 Aug;35(2):95-105
references.pmid: 11707316
references.citation: Eur J Pharmacol. 1983 Jul 22;91(2-3):189-96
references.pmid: 6617740
references.citation: Psychopharmacology (Berl). 1980;68(3):209-15
references.pmid: 6771804
references.citation: Pharmacol Biochem Behav. 1980 Oct;13(4):569-74
references.pmid: 6449014
references.citation: Neuropsychopharmacology. 2002 Apr;26(4):552-6
references.pmid: 11927180
references.citation: Curr Opin Pharmacol. 2007 Apr;7(2):146-50
references.pmid: 17284360
references.citation: Psychopharmacology (Berl). 1995 Oct;121(3):364-72
references.pmid: 8584619
references.citation: Neuropharmacology. 2005 Dec;49(8):1210-9
references.pmid: 16165167
references.citation: Behav Pharmacol. 2007 Jul;18(4):283-8
references.pmid: 17551320
references.citation: Pharmacol Rev. 1996 Sep;48(3):413-63
references.pmid: 8888308
references.citation: Mol Pharmacol. 1999 May;55(5):863-72
references.pmid: 10220565
references.citation: Br J Pharmacol. 2000 Feb;129(4):820-1
references.pmid: 10683207
references.citation: Bioorg Med Chem. 2000 Oct;8(10):2427-32
references.pmid: 11058037
references.citation: Biochem Pharmacol. 2006 Jun 14;71(12):1663-70
references.pmid: 16460689
references.citation: Neuropharmacology. 1993 Dec;32(12):1427-32
references.pmid: 8152532
references.citation: J Pharmacol Exp Ther. 2008 Feb;324(2):827-33
references.pmid: 17993605
references.citation: Proc Natl Acad Sci U S A. 1989 Oct;86(19):7321-5
references.pmid: 2552439
references.citation: Psychopharmacology (Berl). 1998 May;137(2):157-63
references.pmid: 9630002
references.citation: J Biol Chem. 1994 Apr 22;269(16):11687-90
references.pmid: 7909313
references.citation: Pharmacol Biochem Behav. 1982 Apr;16(4):553-6
references.pmid: 7071088
references.citation: Neuropsychopharmacology. 2002 Mar;26(3):340-7
references.pmid: 11850148
references.citation: J Biol Chem. 1999 Apr 2;274(14):9472-8
references.pmid: 10092629
references.citation: Neuropharmacology. 2003 Apr;44(5):604-15
references.pmid: 12668046
references.citation: J Pharmacol Exp Ther. 1995 Nov;275(2):1050-7
references.pmid: 7473132
references.citation: Arch Int Pharmacodyn Ther. 1954 Sep 1;99(1):32-49
references.pmid: 13229418
references.citation: Pharmacol Biochem Behav. 2000 Sep;67(1):103-10
references.pmid: 11113489
references.citation: Eur J Pharmacol. 1994 Oct 13;264(1):99-102
references.pmid: 7530204
references.citation: Learn Mem. 2003 Sep-Oct;10(5):355-62
references.pmid: 14557608
references.citation: Trends Pharmacol Sci. 2006 Feb;27(2):92-6
references.pmid: 16406086
references.citation: J Pharmacol Exp Ther. 2004 Sep;310(3):865-70
references.pmid: 15113845
references.citation: Pharmacol Biochem Behav. 2002 May;72(1-2):77-85
references.pmid: 11900772
references.citation: Pharmacol Ther. 2009 Feb;121(2):160-73
references.pmid: 19109993
references.citation: J Pharmacol Exp Ther. 2001 Oct;299(1):268-76
references.pmid: 11561089
references.citation: Psychopharmacology (Berl). 2006 Jan;184(2):173-81
references.pmid: 16369834
references.citation: Pharmacol Biochem Behav. 1975 May-Jun;3(3):429-35
references.pmid: 125425
references.citation: Psychopharmacology (Berl). 1999 Jan;141(2):162-8
references.pmid: 9952040
references.citation: Behav Pharmacol. 1991 Jun;2(3):225-231
references.pmid: 11224066